The Experience of Using the Brentuximab Vedotin in the Treatment of Children and Young Adults With Primary Refractory Course and Relapses of Hodgkin's Lymphoma

Pediatric Hematology/Oncology and Immunopathology - Russian Federation
doi 10.24287/1726-1708-2020-19-1-47-52
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Fund Doctors, Innovations, Science for Children

Related search

Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas

Klinicheskaya Onkogematologiya/Clinical Oncohematology
OncologyHematology
2016English

Profile of Brentuximab Vedotin and Its Potential in the Treatment of Relapsed or Refractory Hodgkin Lymphoma

Blood and Lymphatic Cancer: Targets and Therapy
2012English

Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Annals of Hematology
MedicineHematology
2014English

Brentuximab Vedotin and Bendamustine as Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: A Multicentre Experience of the Polish Lymphoma Research Group

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Response-Adapted Treatment With Nivolumab and Brentuximab Vedotin in Young Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Checkmate 744 Subgroup Analyses

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Our First Experiences With Brentuximab Vedotin in the Treatment of Cutaneous T-Cell Lymphoma

Bőrgyógyászati és Venerológiai Szemle
2019English

Targeted Drug Brentuximab Vedotin for Treatment of Relapsed or Refractory Cd30-Positive Hodgkin’s Lymphoma

Malignant tumours
2017English

Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure – Polish Lymphoma Research Group Real-Life Experience

Acta Haematologica Polonica
OncologyHematology
2018English

Successful Rapid Desensitization to the Antibody–drug Conjugate Brentuximab Vedotin in a Patient With Refractory Hodgkin Lymphoma

Journal of Oncology Pharmacy Practice
MedicineOncologyPharmacology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy